I'm dying to read it and can't figure out these combinations that some are posting here.
This old fart ain't bright enough to figure that stuff out.
Don't forget all those stock options that he has.
When you name the current CFO the new CEO your probably looking at a temp situation meaning a sale is coming probably fairly soon.
Btw visible size bids keep appearing today.
This is new meaning something that I haven't seen here in months.
Not enough selling for just about anyone to be dumping.
Nobody wants to let it go at this price.
Imagine a stock that is heavily institutional owned. imagine further that these institutions are now seasoned veterans from all the nonsense thrown b at them over the last year.
Add on to that the fact that earnings could/should surprise to the upside every quarter for the rest of the year and you have the makings of a stock where there are no shares to get to cover. Not often you see over 100% of the float owned by tutes.
Does this drug even have any sales in the US?
If so I don't think it amounts to a hill of beans.. Antitrust agents have better things to do, imo...
Predicting a number is a tough game.
One thing we have going for us here is the company buyback program. Of all the companies that I have invested in this one has used it more than any.
Removing stock from the float enhances earnings in a fashion that if this company buys back as many more shares as it has in the past were going to your number and perhaps higher.
Seems like what your saying is that with Questors experience at getting into the doctors and with a nice price raise that this drug will be an outstanding revenue itrem for both companies.
Have you considered making contact with the writer of the NYT piece to see if he might do a follow up piece or for that matter another paper?
It seem that you have developed quite a story here.
I'm impressed and now understand all of your comments over the last couple months about knowing more than us. Its clear that you really do.
I agree in that after Q2 results are out there will be much better understanding of what earnings going forward will be.
Further with the events of the last week one would expect some pretty good questions to be put to the company on sales going forward.
I seldom listen to these CC's but the next one will have me on it.
Not going to guess the numbersd but do expect the whole crowd to be raising them.
This is as tough call.
I'm inclined to think that on the heavy volume day we had both covering and new shorting.
Mikey's number is probably close.
I would project them as sucessful even without attending because I believe we all know what they said to this group..
Usually when an institution attends a setting like this he than has to go back and sell his new ideas to his group before there is buying unless they already own the stgock in which case the buying can start much faster.
Typically there is a few days lagtime before you will see new buyers get involved.